Levetiracetam
- Atc Codes:N03AX14
- CAS Codes:102767-28-2
- PHARMGKB ID:102767-28-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Keppra; Belgium: Keppra; Bulgaria: Keppra; Cyprus: Keppra; Czech Republic: Keppra; Denmark: Keppra; Estonia: Keppra; Finland: Keppra; France: Keppra; Germany: Keppra; Greece: Keppra; Hungary: Keppra; Ireland: Keppra; Italy: Keppra; Latvia: Keppra; Lithuania: Keppra; Luxembourg: Keppra; Malta: Keppra; Netherlands: Keppra; Poland: Keppra; Portugal: Keppra; Romania: Keppra; Slovakia: Keppra; Slovenia: Keppra; Spain: Keppra; Sweden: Keppra; UK: Keppra.
North America
Canada: Keppra, Levetiracetam; USA: Keppra, Levetiracetam.
Latin America
Argentina: Callexe, Keppra, Levron; Mexico: Keppra.
Drug combinations
Chemistry
Levetiracetam: C~8~H~14~N~2~O~2~. Mw: 170.21. (1) 1-Pyrrolidineacetamide, α-ethyl-2-oxo-, (α S)-; (2)(-)-(S) – α-Ethyl-2-oxo-1-pyrrolidineacetamide. CAS-102767-28-2 (1999).
Pharmacologic Category
Anticonvulsants, Miscellaneous. (ATC-Code: N03AX14).
Mechanism of action
The precise mechanism by which levetiracetam exerts its antiepileptic effect is unknown and does not appear to derive from any interaction with known mechanisms involved in inhibitory and excitatory neurotransmission.
Therapeutic use
Adjunctive therapy in treatment of partial onset, myoclonic, and/or primary generalized tonic-clonic seizures.
Pregnancy and lactiation implications
Unlabeled use
Bipolar disorder.
Contraindications
Hypersensitivity to levetiracetam or any component of the formulation.
Warnings and precautions
CNS effects (weakness, dizziness, and somnolence) occur mostly during the 1^st^ month of therapy. Hematologic effects (decreases in red blood cell counts, hemoglobin, hematocrit, white blood cell counts and neutrophils) observed. Psychotic symptoms: psychosis, hallucinations and behavioral symptoms (including aggression, anger, anxiety, depersonalization, depression, personality disorder) may occur. Use caution with renal impairment. Effects with other sedative drugs or ethanol may be potentiated. Children may have increased incidence of psychotic symptoms. Should not be discontinued abruptly.